Pediatrix Medical Group, Inc.
MDdata completeness 75%18 fiscal years on fileData notes: no data for concept 'capex'
Pediatrix Medical Group, Inc. earns about 9% on invested capital, with a roughly flat share count. The applicable estimate puts fair value near $8.06 a share.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $1.91B1 | $1.97B2 | $1.99B3 | $2.01B3 | $1.91B3 |
| Net income | $131M4 | $66.3M5 | −$60.4M6 | −$99.1M6 | $165.4M6 |
| Operating cash flow | $76.7M7 | $166.9M8 | $137.3M9 | $206.6M9 | $271.1M9 |
| Capital expenditure | — | — | — | — | — |
| Free cash flow (derived) | — | — | — | — | — |
| Total debt | $989.7M10 | $637.2M11 | $622.2M12 | $611.2M12 | — |
| Cash & equivalents | $387.4M13 | $9.82M14 | $73.3M15 | $229.9M16 | $375.2M16 |
| Diluted shares | 85.8M | 84.1M | 82.2M | 83.3M | 85.3M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $101.55 of net worth that earned you $19.4 last year.
It earned an average 9% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is roughly flat over 5 years — little dilution, little buyback. Total debt has fallen 38% — deleveraging.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
assumptions (8)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- normalizedEarnings$66.3M
- growthAssumed0.0%
assumptions (1)
- grahamMultiplier2250.0%
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0000950170-24-016794 (RevenueFromContractWithCustomerIncludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-023730 (RevenueFromContractWithCustomerIncludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-058074 (RevenueFromContractWithCustomerIncludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-016794 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-023730 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-058074 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0000950170-24-016794 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0000950170-25-023730 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001193125-26-058074 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0000950170-23-003127 (LongTermDebt)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-016794 (LongTermDebt)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-023730 (LongTermDebt)
- 10-K · period ending 2021-12-31 · accession 0000950170-23-003127 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0000950170-24-016794 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0000950170-25-023730 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001193125-26-058074 (CashAndCashEquivalentsAtCarryingValue)